Key clinical point: Insurance status is significantly associated with survival disparities in patients with follicular lymphoma.
Major finding: The risk for death among patients under age 65 with no insurance, Medicaid, or Medicare was nearly twice that of similar patients with private health insurance.
Study details: Review of data on 43,648 patients with follicular lymphoma in the National Cancer Database.
Disclosures: The study was supported by Emory University, the National Institutes of Health, and the National Center for Advancing Translational Sciences. Dr. Flowers reported financial relationships with AbbVie, Spectrum, Celgene, and several other companies. The other authors reported having nothing to disclose.
Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035.
This Week's Must Reads
Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.
Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.
Adjuvant doxorubicin and ifosfamide boost outcomes in soft tissue sarcomas, Pasquali S et al. ASCO 2018, Abstract 115118.
Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030
Indolent course found in rare clear cell papillary RCC , Chen W-J et al. J Chinese Med Assoc. 2018 July 20 doi: 10.1016/j.jcma.2018.04.005
Must Reads in Lymphoma & Plasma Cell Disorders
Private Insurance Linked to Better Outcomes in Follicular Lymphoma, Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035.
PET/CT provides MCL staging information, Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.
Durable responses seen from lisocabtagene in relapsed/refractory DLBCL, Abramson JS et al. ASCO 2018. Abstract 7505
Revised International Pediatric Non-Hodgkin Lymphoma Staging System, Expert panel publishes evidence-based system
Link Between Vitamin D and Lymphoma Survival, Analysis of patients in SWOG and LYSA trials